Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6690772 | 0.86 | HTT (0.57) | HTTFFAR1METAP2MEN1CYP1A2 | |
| SCHEMBL28855181 | 0.82 | FFAR1 (0.53) | HTTFFAR1METAP2MEN1KMT2A | |
| SCHEMBL15576268 | 0.82 | HDAC4 (0.56) | HTTHDAC4MEF2DFFAR1METAP2 | |
| SCHEMBL5144284 | 0.82 | RAPGEF4 (0.53) | HDAC4MEF2DSMN1; SMN2RAPGEF4MEN1 | |
| SCHEMBL15474335 | 0.82 | MEN1 (0.66) | HTTSMN1; SMN2FFAR1MEN1CYP1A2 | |
| SCHEMBL28636989 | 0.81 | RAPGEF4 (0.46) | HDAC4SMN1; SMN2RAPGEF4TP53HDAC11 | |
| SCHEMBL1681160 | 0.81 | HTR6 (0.54) | HTTFFAR1METAP2CYP1A2CYP2C9 | |
| SCHEMBL1520656 | 0.81 | FFAR1 (0.55) | HTTFFAR1METAP2PTPN1PTPN11 | |
| SCHEMBL259701 | 0.81 | MAPT (0.65) | HTTSMN1; SMN2MEN1CYP1A2CYP3A4 | |
| SCHEMBL27840632 | 0.80 | HTT (0.49) | HTTFFAR1METAP2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| WO-2018188990-A1 | BIOTIN-CONJUGATED N-ACETYL GLYCOL SPLIT HEPARIN | LEADIANT BIOSCIENCES SA IN LIQUIDAZIONE (CH) | 2018-10-18 | — | — | WO | disclosed |
| EP-3388419-A1 | GLI1 INHIBITORS AND USES THEREOF | Leadiant Biosciences SA (CH) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388439-A1 | BIOTIN-CONJUGATED N-ACETYL GLYCOL SPLIT HEPARIN | Leadiant Biosciences SA (CH) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018177865-A1 | COMPOUNDS FOR USE AS HEPARANASE INHIBITORS | LEADIANT BIOSCIENCES SA IN LIQUIDAZIONE (CH) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018177857-A1 | SYMMETRICAL 2-AMINOPHENYL-BENZAZOLYL-5-ACETATE COMPOUNDS AND THEIR USE AS ANTI-HEPARANASE | LEADIANT BIOSCIENCES SA IN LIQUIDAZIONE (CH) | 2018-10-04 | — | — | WO | disclosed |
| EP-3381906-A1 | COMPOUNDS FOR USE AS HEPARANASE INHIBITORS | Leadiant Biosciences SA (CH) | 2018-10-03 | — | — | EP | disclosed |
| EP-3381907-A1 | SYMMETRICAL 2-AMINOPHENYL-BENZAZOLYL-5-ACETATE COMPOUNDS AND THEIR USE AS ANTI-HEPARANASE | Leadiant Biosciences SA (CH) | 2018-10-03 | — | — | EP | disclosed |
| EP-2970303-B3 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9987266-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-05 | — | — | US | disclosed |
| WO-2006116615-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | HYPNION, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1697349-A1 | DOXEPIN ANALOGS AND METHODS OF USE THEREOF | Hypnion, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050256165-A1 | Doxepin analogs and methods of use thereof | HYPNION, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005105110-A2 | DOXEPIN ANALOGS AND METHODS OF USE THEREOF | HYPNION, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005102335-A2 | METHODS OF TREATING SLEEP DISORDERS | HYPNION, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050171160-A1 | Doxepin analogs and methods of use thereof | HYPNION, INC. | 2005-08-04 | — | — | US | disclosed |
| WO-2005058880-A1 | DOXEPIN ANALOGS AND METHODS OF USE THEREOF | HYPNION, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20020156097-A1 | Salts of quinoline derivatives as NK3 antagonists | SMITHKLINE BEECHAM S.P.A. | 2002-10-24 | — | — | US | disclosed |
| US-4732897-A | 4-AZA-17-BETA-SUBSTITUTED-5-ALPHA ANDROSTAN-3-ONES | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1988-03-22 | — | — | US | disclosed |
| EP-0200859-A1 | Steroidal 5-alpha-reductase inhibitors, processes for their preparation and pharmaceutical compositions containing them | FARMITALIA CARLO ERBA S.p.A. (IT) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | RORC, RORB, RORA | HTT 4328/4885HDAC4 442/4885MEF2D 3372/4885 |
| US-20050171160-A1 | Doxepin analogs and methods of use thereof | MME, DPEP1, CES2 | HTT 1251/4885HDAC4 522/4885MEF2D 2594/4885 |
| US-20050256165-A1 | Doxepin analogs and methods of use thereof | MME, DPEP1, CES2 | HTT 1251/4885HDAC4 522/4885MEF2D 2594/4885 |
| US-20020156097-A1 | Salts of quinoline derivatives as NK3 antagonists | KCNK3, KCNQ3, KCNN3 | HTT 3681/4885HDAC4 1379/4885MEF2D 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.